ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.065,44
-1,55%
S&P 500
5.702,55
-0,19%
US Dollar vs BRL
5,5146
1,64%
Bitcoin
63.200,79
0,40%
Brent Oil
74,135
-0,25%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) Notícias

SAN

Sanofi (SAN)

Sanofi
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:EU:SAN
DataHoraFonteTítuloCódigoCompanhia
20/09/202419:36GlobeNewswire Inc.Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplantEU:SANSanofi
20/09/202408:45GlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year oldEU:SANSanofi
20/09/202406:30GlobeNewswire Inc.Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyEU:SANSanofi
13/09/202413:15GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)EU:SANSanofi
12/09/202402:00GlobeNewswire Inc.Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersEU:SANSanofi
02/09/202402:00GlobeNewswire Inc.Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosisEU:SANSanofi
08/08/202402:00GlobeNewswire Inc.Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantEU:SANSanofi
25/07/202411:56GlobeNewswire Inc.Press Release: Online availability of Sanofi’s half-year financial report for 2024EU:SANSanofi
25/07/202402:30GlobeNewswire Inc.Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedEU:SANSanofi
17/07/202418:27GlobeNewswire Inc.Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AEU:SANSanofi
03/07/202402:00GlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
03/07/202402:00GlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneEU:SANSanofi
26/06/202418:30GlobeNewswire Inc.Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMEU:SANSanofi
26/06/202418:30GlobeNewswire Inc.Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ansEU:SANSanofi
25/06/202414:32GlobeNewswire Inc.Press Release: Availability of the Q2 2024 Aide-mémoireEU:SANSanofi
25/06/202414:32GlobeNewswire Inc.Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »EU:SANSanofi
21/06/202404:30GlobeNewswire Inc.Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive CommitteeEU:SANSanofi
21/06/202404:30GlobeNewswire Inc.Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de SanofiEU:SANSanofi
21/06/202402:00GlobeNewswire Inc.Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilieEU:SANSanofi
21/06/202402:00GlobeNewswire Inc.Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranEU:SANSanofi
20/06/202409:00GlobeNewswire Inc.Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in AfricaEU:SANSanofi
20/06/202409:00GlobeNewswire Inc.Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en AfriqueEU:SANSanofi
12/06/202415:19GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024EU:SANSanofi
12/06/202415:19GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares – May 2024EU:SANSanofi
03/06/202417:15GlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
03/06/202417:15GlobeNewswire Inc.Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]EU:SANSanofi
31/05/202407:00GlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
31/05/202407:00GlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
31/05/202402:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
31/05/202402:05GlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
 Apresentando as notícias mais relevantes sobre:EU:SAN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
JFEN3
JOAO FORTES ON
BOV
AZEV4
AZEVEDO PN
BOV
COGN3
COGNA ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
PRIO3
PETRORIO ON
BOV
OIBR3
OI ON
BOV
GFSA3
GAFISA ON
BOV
AZEV3
AZEVEDO ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
RCSL4
RECRUSUL PN
BOV
VVEO3
CM Hospitalar ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
TELB4
TELEBRAS PN
BOV
CVCB3
CVC BRASIL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados